CRISPR Therapeutics price to sales ratio CRSP

Market value divided by revenue over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; a sliver of sales
Last meaningful: 121×; Feb 2026
10-year median: 33.0×
10-year range: 4.0× to 186×
Peer median: 7.5×

CRISPR Therapeutics' price to sales ratio is not a meaningful number today: a multiple this high rests on a sliver of sales.

It was last meaningful in Feb 2026, at 121×.

On the days it had one over the last ten years, its median was 33.0×, from 4.0× in May 2022 to 186× in Mar 2018.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	121×	121×	138×
2025	137×	16.7×	175×
2024	16.8×	11.7×	38.4×
2023	29.2×	18.0×	51.2×
2022	6.9×	4.0×	7.1×
2021	6.4×	5.9×	183×
2020	140×	7.9×	154×
2019	17.1×	13.1×	54.5×
2018	39.3×	33.4×	186×
2017	87.4×	65.0×	168×

Against its peers

Companies in Biotechnology nearest CRISPR Therapeutics' size, closest first, today.

Company	Price to sales ratio
CRSPCRISPR Therapeutics	n/m
KRYSKrystal Biotech	20.9×
ADMAAdma Biologics	4.7×
RGENRepligen	12.7×
VCELVericel	7.1×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
INCYIncyte	4.0×
UTHRUnited Therapeutics	8.0×
Peer median	7.5×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on CRISPR Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.